Get Our FREE Newsletter

Sign Up

Accuray's CyberKnife Reduces Incidence Of Bladder Side Effects In Prostate Cancer Patients

Spread the love

(RTTNews) – Accuray Inc. (ARAY) said data from the Prostate Advances in Comparative Evidence or PACE trial indicated that the company’s CyberKnife robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or higher b

This post was originally published on this site